An Interleukin-1 Binding Region Oligopeptide from the Human Type I IL-1 Receptor Reduces Acute Inflammation, Delayed Hypersensitivity Reaction, and Lethal Endotoxemia in Animals
| Autor: | Miyako Nakagawa, Yasuo Suzuki, Yutaka Mizushima, Masao Tanihara, Yoichi Ichikawa, Kyoko Terasawa, Chieko Masuda, Asako Furukawa |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Lipopolysaccharides
medicine.medical_specialty Lipopolysaccharide Immunology Peptide Inflammation Biology Mice chemistry.chemical_compound Colony-Stimulating Factors Virology Internal medicine Extracellular medicine Animals Humans Hypersensitivity Delayed Rats Wistar Receptor chemistry.chemical_classification Immunity Cellular Mice Inbred BALB C Oligopeptide Sheep Receptors Interleukin-1 Interleukin Cell Biology Hypoglycemia Rats Mice Inbred C57BL Survival Rate Endocrinology chemistry Delayed hypersensitivity Acute Disease Female medicine.symptom Oligopeptides |
| Zdroj: | Journal of Interferon & Cytokine Research. 15:1083-1088 |
| ISSN: | 1557-7465 1079-9907 |
| DOI: | 10.1089/jir.1995.15.1083 |
| Popis: | The effect of an interleukin-1 binding region oligopeptide from the interleukin-1 receptor on various inflammatory responses was investigated in animal models. A synthetic peptide (KICIRIQIS) corresponding to 86-93 of the extracellular domain of the human type I interleukin-1 receptor was used. Carrageenan-induced rat paw edema, a model of acute inflammation, was dose dependently suppressed by intraperitoneal administration of the peptide. The delayed hypersensitivity reaction to sheep red cells was diminished by pretreatment of mice with the peptide at a relatively high dose. In a murine lethal endotoxemia model, animals treated with the interleukin-1 receptor peptide (10 mg/kg x 4) showed significantly better survival than vehicle-treated animals when the peptide was administered from 20 minutes after lipopolysaccharide injection. Improved survival was accompanied by suppression of lipopolysaccharide- induced production of colony-stimulating factor, although the peptide did not improve hypoglycemia. These findings suggest that the interleukin-1 receptor peptide may be a potential treatment for various inflammatory processes. — |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|